Anove LogoAnove LogoExplAIn
MapsAI frontrunners
Back to Directory

AISight Dx

by PathAI

AI Application
Low Confidence

AISight Dx is PathAI's digital pathology platform and image management system for pathology laboratories and academic centres. The vendor says pathologists use it to view, interpret, share and manage whole-slide images, and that AI runs inside the slide viewer: PathAI's own workflow algorithms for quality control, prioritising cases in which suspicious tissue is found and assessing tumour cellularity before sequencing, plus more than 40 third-party algorithms, for example for PD-L1, HER2, Ki-67 and other biomarkers, each with its own regulatory status. The vendor says its automated case review, assisted diagnosis, reporting and finalisation features are research-use only and not for primary diagnosis, so the diagnosis stays with the pathologist reading the slides. It describes the platform as cloud-native, and for a European deployment announced in 2025 says all data storage and processing remain within Europe; its general privacy notice says its platforms are operated and hosted from the United States.

Visit Website

Transparency Score

Weighted across four pillars · updated October 20, 2026

Overall grade
37% weighted
ABCDF
Model
—
Not yet assessed
Infrastructure
—
Not yet assessed

Capabilities

Whole Slide Image Management
Case Prioritisation
Slide Quality Control
Tumour Cellularity Assessment
Ai Algorithm Hosting

Vendor Information

Complete information about the vendor/provider of this AI application

PathAIView all products →
PathAI, Inc.
Contact Information
www.pathai.com/
privacy@pathai.com
(617) 500-8457
Registered Address
1325 Boylston St., Suite 10000, Boston, MA, 02215, US

EU AI Act Provider Information

Verification Status:
Unverified
PathAI, Inc.
1325 Boylston St., Suite 10000, Boston, MA, 02215, US
privacy@pathai.com(617) 500-8457
MDSS GmbH
Schiffgraben 41, Hannover, DE
Compliance Documents
CE Marking: Certified
PathAI says the automation in case review, assisted diagnosis, reporting and finalisation features of AISight Dx are research-use only and not for primary diagnostic use, and that some features are in development and available to select partners only (https://www.pathai.com/aisightdx-digital-pathology-solution/eu, read 2026-10-20). Its broader algorithm portfolio (AIM-PD-L1, AIM-MASH, AIM-Breast, PathAssist Derm) is research-use only in the EU (same page).

Potential Risks

1 considerations identified

1

Review recommended before use

These considerations are automatically identified based on publicly available information about the vendor and AI catalog data. Actual risks may vary based on your specific use case and implementation.

Compliance & Risk

Get insights into risk by running assessments on this AI application.

Work at PathAI? Claim this listing to correct or complete the data.

Added: February 23, 2026
Updated: October 20, 2026

Ready to manage AI applications?

Track, assess, and govern your AI applications with Anove.

Anove LogoAnove LogoAnove International B.V.

Helping organizations discover and manage AI applications responsibly. Your trusted source for AI governance and compliance.

Quick Links

  • Browse Directory
  • FAQ
  • AI maps by industry
  • Sign In

Resources

  • Documentation
  • Status
  • Anove.ai

Terms

  • Privacy Policy
  • Terms & Conditions
  • Responsible Disclosure
  • AI Legal Notice
  • Security Policy

© 2026 Anove International B.V. All rights reserved.